Skip to main content
TipRanks
Go Ultimate75% OFF

Oncolys BioPharma, Inc. (4588) AI Stock Analysis

1 Followers
JP:4588

Oncolys BioPharma, Inc.

(TSE/TYO:4588)

Select Model
Rating:55Neutral
Price Target:JPY 8,620.00â–²(13.12% Upside)
Action:reiterated
Date:09/19/26

The overall score of 55 is constrained primarily by weak financial fundamentals and a highly speculative valuation, though it is buoyed by exceptionally strong technical momentum. While the company operates with significant cash burn and deep negative earnings typical of pre-revenue biotechs, a recently replenished equity base provides a critical liquidity buffer. The stock exhibits powerful upward price action across all major moving averages, highlighting immense market interest despite the underlying lack of profitability.

Positive Factors
Manageable LeverageImproved leverage gives Oncolys greater financial flexibility than a highly indebted biotechnology peer. Lower debt relative to equity can reduce balance-sheet pressure, preserve borrowing capacity, and provide more room to fund clinical development while the company works toward commercial scale.
Negative Factors
Severe Revenue DeclineThe sharp multi-year revenue contraction indicates that current commercial or partnership-related income is not supporting a reliable growth trajectory. Rebuilding revenue from this reduced base would require a major product, licensing, or milestone inflection, leaving fundamentals weak over the next several quarters.

Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)

-200%0%200%400%600%800%JP:4588+649.26%EWJ+14.66%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 233.17B
Dividend Yield
―
Average Volume (3M)
1.76M
Price to Earnings (P/E)
-138.2
Beta (1Y)
1.96
Revenue Growth
1748.97%
EPS Growth
35.11%
Country
Japan
Employees
42
Sector
General
Sector Strength
55
Industry
Biotechnology

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the Unit...

How the Company Makes Money

Detailed, company-specific revenue breakdown (e.g., product sales by drug, recurring service revenue, or disclosed milestone/royalty structures) is not available in the information provided here; therefore, this data point is null.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Financial performance is heavily impacted by significant net losses and a severe cash burn rate of nearly 2 billion JPY annually, with revenue dropping sharply since 2022. While a low debt-to-equity ratio of 0.08 and recent equity financing provide a stable balance sheet and necessary liquidity runway, the persistent lack of commercial revenue limits this score to the lower bound.

Income Statement

15Very Negative

Balance Sheet

65Positive

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue28.55M28.55M31.38M63.04M976.18M642.49M
Gross Profit28.30M28.30M31.38M30.61M338.49M198.80M
EBITDA-2.05B-2.05B-1.68B-1.93B-1.14B-1.60B
Net Income-2.06B-2.06B-1.68B-1.94B-1.15B-1.62B
Balance Sheet
Total Assets4.56B4.56B3.20B2.04B2.65B4.29B
Cash, Cash Equivalents and Short-Term Investments3.72B3.72B2.41B1.53B1.71B3.45B
Total Debt320.02M320.02M324.64M315.17M393.66M503.47M
Total Liabilities555.91M555.91M446.65M566.50M491.69M697.88M
Stockholders Equity4.00B4.00B2.75B1.47B2.16B3.59B
Cash Flow
Free Cash Flow0-1.94B-2.02B-1.34B-1.72B-1.74B
Operating Cash Flow0-1.94B-2.02B-1.34B-1.72B-1.74B
Investing Cash Flow0-7.58M-4.71M-5.39M20.12M-942.00K
Financing Cash Flow03.22B2.88B1.14B-113.83M3.09B

Oncolys BioPharma, Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price7620.00

Price Trends

50DMA6242.80Positive
100DMA4592.96Positive
200DMA3551.45Positive

Market Momentum

MACD589.91Negative
RSI61.20Neutral
STOCH71.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 7620.00 is above the 20-day moving average (MA) of 7077.00, above the 50-day MA of 6242.80, and above the 200-day MA of 3551.45, indicating a bullish trend. The MACD of 589.91 indicates Negative momentum. The RSI at 61.20 is Neutral, neither overbought nor oversold. The STOCH value of 71.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4588 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4588JP:458855NeutralJPY 225.09B-138.17――1748.97%35.11%
JP:4583JP:458349NeutralJPY 6.14B-6.03――-13.40%7.50%
JP:4587JP:458748NeutralJPY 145.66B-49.95-5.85%―14.25%50.07%
JP:4564JP:456440UnderperformJPY 6.12B-6.52-42.81%―-25.56%17.01%
JP:4575JP:457539UnderperformJPY 13.64B-9.80―――-12.48%

* General Sector Average

Performance Comparison

0%200%400%600%JP:4588JP:4587JP:4564JP:4575JP:4583Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4588 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4588Oncolys BioPharma, Inc.7620.006640.00677.55%
JP:4587Peptidream 1122.00-540.00-32.49%
JP:4564OncoTherapy Science, Inc.15.00-7.00-31.82%
JP:4575CanBas Co., Ltd.690.00-98.00-12.44%
JP:4583Chiome Bioscience Inc.75.00-50.00-40.00%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Higher Sales and Narrower Nine-Month Loss

Nov 6, 2026

Oncolys BioPharma reported net sales of ¥527 million for the nine months ended September 30, 2026, up from ¥28 million a year earlier. Operating loss narrowed to ¥1.104 billion from ¥1.571 billion, while net loss improved to ¥1.115 billion from ¥1.61...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026